Skip to main content

Table 3 Change from baseline in 24-h ambulatory BP and heart rate at 6 and 12 months

From: Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the RECORD study)

  Background metformin Background sulfonylurea
  + rosiglitazone (n = 176) + sulfonylurea (n = 165) difference (95% CI), p-value + rosiglitazone (n = 160) + metformin (n = 167) difference (95% CI), p-value
ystolic BP change (mmHg)
6 months -3.1 (-4.8, -1.4) -1.6 (-3.5, + 0.3) -1.5 (-3.6, 0.6), NS -3.8 (-5.8, -1.8) -1.2 (-3.0, + 0.7) -2.7 (-4.9, -0.5), 0.015
12 months -4.9 (-6.7, -3.2) -2.2 (-4.2, -0.3) -2.7 (-4.9, -0.5), 0.016 -3.8 (-5.9, -1.8) -1.3 (-3.3, + 0.7) -2.5 (-4.8, -0.2), 0.031
Diastolic BP change (mmHg)
6 months -2.8 (-3.8, -1.9) -1.6 (-2.7, -0.5) -1.3 (-2.5, -0.0), 0.049 -3.1 (-4.2, -2.0) -0.4 (-1.6, + 0.7) -2.7 (-4.0, -1.4), < 0.001
12 months -3.8 (-4.9, -2.7) -1.7 (-2.9, -0.5) -2.1 (-3.4, -0.7), 0.003 -3.7 (-4.9, -2.5) -0.6 (-1.7, + 0.6) -3.1 (-4.5, -1.8), < 0.001
Heart rate change (beat/min)
6 months -0.4 (-1.6, + 0.8) -0.1 (-1.3, + 1.0) -0.3 (-1.7, 1.1), NS -0.7 (-1.9, + 0.5) 1.3 (+ 0.1, + 2.6) -2.0 (-3.4, -0.6), 0.006
12 months -0.9 (-2.2, + 0.4) 0.0 (-1.3, + 1.3) -0.9 (-2.5, 0.7), NS -0.9 (-2.3, + 0.5) 1.7 (+ 0.3, + 3.1) -2.6 (-4.2, -1.0), 0.002
  1. Modified ITT population; data are model-adjusted mean (95% CI), or number